


LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
O P STATEMENT

APPLICANT: Gilman

FILING DATE: 10/23/01

GROUP 1632



OTHER ART

(Including Author, Date, Publication, Title, Pertinent Pages)

R/R	PATENT & TRADEMARK OFFICE WASHINGTON, D.C.	
		Hollenberg and Evans, (1988) Cell, 55: 889-906.
10		Tate et al., (1996) FASEB J., 10: 1524-1531.
11		Sauer, (1995) Science 270: 1783-1788.
12		Sublett et al., (1995) Oncogene, Aug 3; 11(3): 545-52.
13		Le Douarin et al., (1995) Nucleic Acids Research, 23: 876-878.
14		Oligino et al., (1996) Gene Therapy, 8: 892-899.
15		Veelken et al., (1998) Int J Mol. Med., 2(4): 423-428.
16		Liu et al., (1993) Immunology Today, 14:290-295, 1993.
17		Orkin et al., (1995) Report & Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy
18		Orloff et al., (1990) Nature 347:189-190.
19		Qi et al., (1995) Mol Cell Biol., 5:1817-1825.
20		Sadowski et al., (1993) Nature 362:79-83.
21		Weintraub et al., (1991) Science 251:761-766.
22		Fishman et al., (1994) J. Clin. Invest. 93:1864-1868.
23		Bergmann et al., (1994) J. Steroid Biochem. Molec. Biol., 49:139-152.
24		Li and Brasler, (1996) Molecular Endocrinology 10:252-264.
25		Baim et al., (1991) Proc Natl Acad Sci USA 88:5072-5076.
26		Prusky et al., (1994) Chemistry & Biology, 1(3): 163-171.
27		Becker et al., (1989) Mol. Cell. Biol., 9(9): 3878-3887.
28		Chapman et al., (1996) Mol. Endocrinol., 10: 967-978.
29		Schmitz and Baeuerle (1991) EMBO J. 10:3805-3817.
30		Selden et al., (1987) Science 236:714-718.
31		Burcin et al., (1999) Proc Natl Acad Sci USA 96:355-360.
32		Rivera et al., (1996) Nature Medicine 2:1028-1032.
33		Rivera et al., (1999) Proc Natl Acad Sci USA 96:8657-8662.
R/R	34	Ye et al., (1999) Science 283:88-91.

R/R12/3/03


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to Applicant.

Form PTO-1449 (Modified)		ATTY. DOCKET NO. 346B USC1	SERIAL NO. 10/002,224
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gilman	
		FILING DATE: 10/23/01	GROUP 1632

JAN 29 2002



U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
RBS		5,830,462	11/3/98	Crabtree et al.	424	93.21	6/7/95
		5,654,168	08/05/97	Bujard et al.	435	69.1	_____
		5,082,670	1/21/92	Gage et al.	424	_____	_____
		5,262,300	11/16/93	Evans et al.	435	6	_____
		5,534,418	7/9/96	Evans et al.	435	69.1	_____
RBS		5,597,693	1/28/97	Evans et al.	435	6	_____

FOREIGN PATENT DOCUMENTS

Exam Init	Ref Des	Country & Doc. No. (11)	Pub. Date (43)	Name	Class	Sub Class	Translation Yes No
RBS		WO 97/12040	4/3/97	Anrather et al.	_____	_____	_____
RBS		WO 96/41865	12/27/96	Clackson et al.	_____	_____	_____
					_____	_____	_____

OTHER ART

(Including Author, Date, Publication, Title, Pertinent Pages)

RBS	1	Ruben et al., (1992) Mol Cell Biol 12:444-454.
	2	Blair et al., (1994) Mol Cell Biol 14:7226-7234.
	3	Emami and Carey (1992) EMBO J. 11:5005-5012.
	4	Kodadek and Johnston (1995) Chemistry and Biology 2:187-194.
	5	Paal (1997) Nucleic Acids Research, 25(5): 1050-1055.
	6	Lin et al., (1988) Cell, 54: 659-664.
	7	Schmitz et al., (1995) J. Biol. Chem., 270: 15576-15584.
RBS	8	White et al., (1992) EMBO J. Jun;11(6):2229-40.

RBS

12/3/03

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to Applicant.